Grifols Price-to-Operating-Cash-Flow

: 9.20 (As of Today)

View and export this data going back to 2011. Start your Free Trial

As of today (2022-08-17), Grifols's share price is $8.84. Grifols's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2022 was $0.96. Hence, Grifols's Price-to-Operating-Cash-Flow Ratio for today is 9.20.

The historical rank and industry rank for Grifols's Price-to-Operating-Cash-Flow or its related term are showing as below:

GRFS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.77 Med: 12.98 Max: 48.12
Current: 17.01

During the past 13 years, Grifols's highest Price-to-Operating-Cash-Flow Ratio was 48.12. The lowest was 6.77. And the median was 12.98.

GRFS's Price-to-Operating-Cash-Flow is ranked better than
51.1% of 683 companies
in the Drug Manufacturers industry
Industry Median: 17.51 vs GRFS: 17.01

Grifols's Cash Flow from Operations per share for the three months ended in Jun. 2022 was $0.00. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2022 was $0.96.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Grifols was -69.20% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -6.70% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 2.80% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 3.30% per year.

During the past 13 years, Grifols's highest 3-Year average Operating Cash Flow per Share Growth Rate was 67.90% per year. The lowest was -19.00% per year. And the median was 11.60% per year.

Grifols Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Grifols's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Price-to-Operating-Cash-Flow

19.86

21.26

37.87

14.74

19.26

Grifols Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22
Price-to-Operating-Cash-Flow																14.74	8.04	10.67	19.26	-

Competitive Comparison

For the Drug Manufacturers - General subindustry, Grifols's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Grifols Price-to-Operating-Cash-Flow Distribution

For the Drug Manufacturers industry and Healthcare sector, Grifols's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Grifols's Price-to-Operating-Cash-Flow falls into.

Grifols Price-to-Operating-Cash-Flow Calculation

Grifols's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	8.84	/	0.961
	=	9.20

Grifols's Share Price of today is $8.84.
Grifols's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.96.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Grifols Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Grifols's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

XMAD:HOME XMAD:COL XMAD:YPER XMAD:REN XMAD:MAP XMAD:ELZ XMAD:FCC XMAD:MRL XMAD:A3M XMAD:BAIN NYSE:JNJ XSWX:ROG NYSE:LLY NYSE:PFE NYSE:ABBV NYSE:MRK LSE:AZN XSWX:NOVN NYSE:BMY XPAR:SAN

Traded in Other Exchanges

GIKLY:USA GIFOF:USA GIFLF:USA GRFP:Mexico GRFE:UK GRFPE:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain G0FB:Germany OZTA:Germany OZTA:Germany G0FB:Germany GRF:Austria

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 77% of sales in 2021. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics is now roughly 15% of revenue following the Novartis and Hologic deals.

Grifols Headlines

From GuruFocus

Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the immune system and develop therapeutics

By PRNewswire 04-28-2021

Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins

By PRNewswire 03-09-2021

Thinking about buying stock in Staffing 360 Solutions, Electrameccanica Vehicles, Grifols SA, Newage Beverage, or Norwegian Cruise Line?

By PRNewswire 10-15-2020

Hansberger Growth Investors, Lp Buys Grifols SA, HDFC Bank, Sells Genmab A/S

By insider 11-12-2020

Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines

By PRNewswire 10-19-2021

Other Sources

$GRFS - Grifols Class B: Buy The Recovery In The U.S. Plasma Business. Grifols Class B Buy Recovery In U S Plasma Business

By Seekingalpha 2020-11-11

$GRFS $GIFLF $GIKLY - Grifols presents at 2021 investor and analyst day - slideshow. Grifols Presents 2021 Investor And Analyst Day Slideshow

By Seekingalpha 2021-06-03

Grifols Price-to-Operating-Cash-Flow

Grifols Price-to-Operating-Cash-Flow Historical Data

Grifols Price-to-Operating-Cash-Flow Calculation

Grifols Price-to-Operating-Cash-Flow Related Terms

Grifols Business Description

Grifols Headlines

Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the immune system and develop therapeutics

Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins

Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR� Center in Barcelona

Grifols Sells Off With Effects of Pandemic

The Dow Jones Sustainability Index recognizes Grifols as one of the world's most sustainable companies

Grifols' anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19

Grifols begins clinical trial of a new treatment that would provide immediate immunity against COVID-19

Thinking about buying stock in Staffing 360 Solutions, Electrameccanica Vehicles, Grifols SA, Newage Beverage, or Norwegian Cruise Line?

Hansberger Growth Investors, Lp Buys Grifols SA, HDFC Bank, Sells Genmab A/S

Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines

$GRFS - Grifols Class B: Buy The Recovery In The U.S. Plasma Business. Grifols Class B Buy Recovery In U S Plasma Business

Is Grifols (GRFS) a Great Value Stock Right Now?

New Strong Sell Stocks for September 22nd

GRFS vs. ZTS: Which Stock Should Value Investors Buy Now?

Should Value Investors Consider Grifols (GRFS) Stock Now?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

$GRFS $GIFLF $GIKLY - Grifols presents at 2021 investor and analyst day - slideshow. Grifols Presents 2021 Investor And Analyst Day Slideshow

Convalescent Plasma Found to Reduce COVID-19 Death Rate in New Study

Grifols (GRFS) to Begin Study on Plasma-Derived COVID-19 Drug

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Moving Average Crossover Alert: Grifols

Better Coronavirus Stock: Grifols or Novartis?

Forget Bargain Hunting: Play 5 Stocks With Rising P/E

New Strong Sell Stocks for January 6th

GRFS vs. ZTS: Which Stock Should Value Investors Buy Now?